Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 94Small Cell Lung Carcinoma 76Neuroblastoma 44Carcinoma, Ovarian Epithelial 43Fallopian Tube Neoplasms 41Lung Neoplasms 39Neoplasms 29Uterine Cervical Neoplasms 26Leukemia 20Brain Neoplasms 18Leukemia, Myeloid, Acute 17Recurrence 16Sarcoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Neoplasm Metastasis 13Lymphoma 12Central Nervous System Neoplasms 12Retinoblastoma 11Glioma 11Carcinoma, Non-Small-Cell Lung 11Sarcoma, Ewing 10Unspecified Adult Solid Tumor, Protocol Specific 8Neuroectodermal Tumors, Primitive, Peripheral 8Myelodysplastic Syndromes 8Medulloblastoma 8Endometrial Neoplasms 8Burkitt Lymphoma 8Lymphoma, Follicular 7Leukemia, Myelomonocytic, Chronic 7Blast Crisis 7

Interventions

niraparib 3Paclitaxel 2Letrozole 2trametinib 1ribociclib 1pembrolizumab 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Specimen Handling 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1CTLA-4 Antigen 1Blood Specimen Collection 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cystadenocarcinoma, Serous × Topotecan × Clear all
NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
260 enrolled 20 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡